Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
NOVAVAX INC
Bear Case (25th pct.)
139.2% vs price
Base Case (Median)
153.9% vs price
Bull Case (75th pct.)
168.5% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| EV/EBITDA | $29.71 | 183.2% | Medium (20%) |
| Earnings Power Value | $23.55 | 124.5% | Medium (50%) |
Based on 2 out of 7 methods, NVAX appears undervalued at the current price of $10.49. The base case fair value of $26.63 implies 153.9% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.